The global lyme disease testing market size was valued at USD 6.7 billion in 2024 and is expected to exhibit growth at a CAGR of 5.7% from 2025 to 2034. The market is driven by several factors that collectively enhance its growth potential. First, the increasing prevalence of Lyme disease, particularly in endemic regions like North America and parts of Europe, significantly boosts the demand for diagnostic tests.
The Centers for Disease Control and Prevention (CDC) 2024, estimates that approximately 476,000 Lyme disease cases are diagnosed annually in the U.S., underscoring the need for robust diagnostic solutions?. Technological advancements in diagnostic methods are another critical driver. The development of highly sensitive and specific technologies, such as molecular diagnostics (e.g., PCR) and next-generation serological assays (e.g., ELISA), enables early and accurate detection, even in asymptomatic patients.
Moreover, point-of-care (POC) tests and at-home testing kits are gaining traction, offering convenient and rapid diagnostic options?. Rising awareness about the long-term complications of untreated Lyme disease, such as chronic neurological and musculoskeletal issues, is prompting early testing and treatment. Public health campaigns by governments and non-profit organizations have significantly contributed to this awareness?. Regulatory support and funding for research into tick-borne diseases are also spurring market growth.
Lyme disease testing involves diagnostic procedures to detect Borrelia burgdorferi, the bacteria responsible for Lyme disease, primarily transmitted through tick bites. Testing methods include serological tests like ELISA and Western blot, molecular diagnostics like PCR, and antigen-based tests. These tests analyze samples such as blood, cerebrospinal fluid (CSF), or urine to identify infection stages, enabling timely and accurate treatment. Early detection is vital to prevent severe complications.
The increasing prevalence of Lyme disease is a significant driver of the market. Lyme disease, caused by the spirochete bacterium Borrelia burgdorferi and transmitted through tick bites, has shown a marked rise in incidence globally, particularly in endemic regions like North America and Europe.
Based on diagnostic technology, the market is segmented into serological test, nucleic acid test, urine antigen testing, lymphocytic transformation test, and immunofluorescent staining. The serological test segment is expected to expand at a CAGR of 6.2%, reaching over USD 5 billion by 2034.
Based on sample type, the lyme disease testing market is classified into blood, urine, CSF, and other blood samples. The blood segment held 52.2% share of the market in 2024, driven by several key factors.
Based on patient type, the lyme disease testing market is patient type into adult and pediatric. The adult segment was valued at USD 4.9 billion in 2024 and is expected to grow at a 6% CAGR between 2025 and 2034.
Based on end use, the lyme disease testing market is segmented into hospitals, diagnostic laboratories, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 5.3 billion by 2034.
U.S. Lyme disease testing market was valued at USD 2.6 billion in 2024 and is projected to grow substantially in the coming years.
U.K. lyme disease testing market is projected to grow remarkably in the coming years.
China holds a dominant position in the Asia Pacific lyme disease testing market.
The market is highly competitive, with several key players leading the industry in terms of market share. Many companies dominate the market with a diverse portfolio of diagnostic products, including advanced serological assays like ELISA and Western blot, as well as molecular testing technologies like PCR. Bio-Rad Laboratories, known for its high-precision diagnostics and extensive global reach, holds a significant portion of the market share due to its widespread use of serological tests in clinical settings. bioMérieux, Inc. is another key player, offering both immunoassays and molecular diagnostics, which contribute to its strong market position, especially in North America and Europe.
The growth in market share of these companies is primarily driven by factors such as technological advancements in diagnostic tools, the increasing prevalence of Lyme disease, and rising awareness about tick-borne infections. Additionally, strategic partnerships and acquisitions among diagnostic companies enhance their product portfolios and expand their geographic presence, enabling them to capture a larger market share. As the global burden of Lyme disease rises, competition will intensify, with companies continually innovating to meet the needs of clinicians and patients alike.
Prominent players operating in the lyme disease testing industry include: